From an applied perspective, the identified mechanism has wide reaching implications for our understanding of the effects of anti-Vegfa therapy in cancer, and will hopefully stimulate new research into dosing regimes of both Vegfa and Dll4/Notch inhibitors, separate and in combination, and effects on vessel normalization. This evidence concerns the gene DLL4 and cancer.